Malaria Vaccines: Progress to Date

Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults

(2022) Said Abdallah Jongo et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Molecular profiling reveals features of clinical immunity and immunosuppression in asymptomatic P. falciparum malaria

(2022) Stephanie I Studniberg et al.   Molecular Systems Biology

Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial

(2022) Aaron M Samuels et al.   LANCET INFECTIOUS DISEASES

Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children

(2022) Gaoqian Feng et al.   BMC Medicine

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

(2022) Mehreen S Datoo et al.   LANCET INFECTIOUS DISEASES

A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection

(2022) Sean C. Murphy et al.   Science Translational Medicine

A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection

(2022) Benjamin Mordmüller et al.   npj Vaccines

In vitro production of infectious Plasmodium falciparum sporozoites

(2022) Abraham G. Eappen et al.   NATURE

A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria

(2022) Sodiomon B. Sirima et al.   Science Translational Medicine

Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver

(2022) Blandine Franke-Fayard et al.   npj Vaccines

Plasmodium infection and drug cure for malaria vaccine development

(2021) Reshma J. Nevagi et al.   Expert Review of Vaccines

Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing

(2021) DeAnna J. Friedman-Klabanoff et al.   VACCINE

Structural basis for placental malaria mediated by Plasmodium falciparum VAR2CSA

(2021) Rui Ma et al.   Nature Microbiology

Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice

(2021) Sara A. Healy et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

(2021) Mehreen S Datoo et al.   LANCET

Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial

(2021) Zita Sulyok et al.   Nature Communications

Combining malaria vaccination with chemoprevention: a promising new approach to malaria control

(2021) Brian Greenwood et al.   MALARIA JOURNAL

Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity

(2021) Agnes Mwakingwe-Omari et al.   NATURE

Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial

(2021) Martina Oneko et al.   NATURE MEDICINE

Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention

(2021) Daniel Chandramohan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evidence of Artemisinin-Resistant Malaria in Africa

(2021) Betty Balikagala et al.   NEW ENGLAND JOURNAL OF MEDICINE

PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection

(2021) Sean C. Murphy et al.   PLoS Pathogens

Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine

(2021) Rebecca Webster et al.   BMC Medicine

A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge

(2021) James E. Moon et al.   VACCINE

Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial

(2021) Mahamadou S Sissoko et al.   LANCET INFECTIOUS DISEASES

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

(2020) Sodiomon B Sirima et al.   LANCET INFECTIOUS DISEASES

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naïve Adults

(2020) James E Moon et al.   JOURNAL OF INFECTIOUS DISEASES

A replication-competent late liver stage–attenuated human malaria parasite

(2020) Debashree Goswami et al.   JCI Insight

Multidose Priming and Delayed Boosting Improve PfSPZ Vaccine Efficacy against Heterologous P. falciparum Controlled Human Malaria Infection

(2020) Kirsten E Lyke et al.   CLINICAL INFECTIOUS DISEASES

Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults

(2020) Said A. Jongo et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria

(2019) Benjamin Mordmüller et al.   CLINICAL INFECTIOUS DISEASES

Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure

(2019) Liriye Kurtovic et al.   BMC Medicine

Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study

(2019) Rob W van der Pluijm et al.   LANCET INFECTIOUS DISEASES

Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults

(2019) Said A Jongo et al.   CLINICAL INFECTIOUS DISEASES

Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoites Vaccine in Tanzanian Adults

(2018) Said A. Jongo et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults

(2018) Issaka Sagara et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults

(2018) Jessica A. Chichester et al.   VACCINE

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

(2018) Tommy Rampling et al.   npj Vaccines

Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study

(2018) Danielle I. Stanisic et al.   BMC Medicine

Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2

(2018) Jean Claude Dejon-Agobe et al.   CLINICAL INFECTIOUS DISEASES

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

(2018) Alfred B. Tiono et al.   PLoS One

Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial

(2017) Mahamadou S Sissoko et al.   LANCET INFECTIOUS DISEASES

Sterile protection against human malaria by chemoattenuated PfSPZ vaccine

(2017) Benjamin Mordmüller et al.   NATURE

Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic

(2017) Benjamin Blasco et al.   NATURE MEDICINE

Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

(2017) Kirsten E. Lyke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine

(2017) Katharine A. Collins et al.   Scientific Reports

Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial

(2016) Guido J. H. Bastiaens et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Declining Efficacy of Artemisinin Combination Therapy AgainstP. FalciparumMalaria on the Thai–Myanmar Border (2003–2013): The Role of Parasite Genetic Factors

(2016) Aung Pyae Phyo et al.   CLINICAL INFECTIOUS DISEASES

Demonstration of the Blood-StagePlasmodium falciparumControlled Human Malaria Infection Model to Assess Efficacy of theP. falciparumApical Membrane Antigen 1 Vaccine, FMP2.1/AS01

(2016) Ruth O. Payne et al.   JOURNAL OF INFECTIOUS DISEASES

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study

(2016) Jason A. Regules et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01BWith Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

(2016) Tommy Rampling et al.   JOURNAL OF INFECTIOUS DISEASES

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

(2016) Andrew S Ishizuka et al.   NATURE MEDICINE

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children

(2016) Ally Olotu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insecticide Resistance in African Anopheles Mosquitoes: A Worsening Situation that Needs Urgent Action to Maintain Malaria Control

(2016) Hilary Ranson et al.   TRENDS IN PARASITOLOGY

A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children

(2016) Sodiomon B. Sirima et al.   VACCINE

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults

(2016) Kawsar R. Talaat et al.   PLoS One

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal

(2016) Victorine A. Mensah et al.   PLoS One

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

(2015)   LANCET

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

(2015) Michael T White et al.   LANCET INFECTIOUS DISEASES

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

(2015) Daniel E. Neafsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

(2015) Christian F. Ockenhouse et al.   PLoS One

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

(2015) Caroline Ogwang et al.   Science Translational Medicine

Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults

(2014) Kent E. Kester et al.   VACCINE

Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites

(2014)   PLOS MEDICINE

Cross-species malaria immunity induced by chemically attenuated parasites

(2013) Michael F. Good et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data

(2013) Philip Bejon et al.   LANCET INFECTIOUS DISEASES

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

(2013) Salim Abdulla et al.   MALARIA JOURNAL

Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure

(2013) Ally Olotu et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity

(2013) Ilin Chuang et al.   PLoS One

Phase 1b Randomized Trial and Follow-Up Study in Uganda of the Blood-Stage Malaria Vaccine Candidate BK-SE36

(2013) Nirianne Marie Q. Palacpac et al.   PLoS One

Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity

(2013) E. M. Bijker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine

(2013) R. A. Seder et al.   SCIENCE

Escaping the immune system: How the malaria parasite makes vaccine development a challenge

(2013) Danielle I. Stanisic et al.   TRENDS IN PARASITOLOGY

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Superior Antimalarial Immunity after Vaccination with Late Liver Stage-Arresting Genetically Attenuated Parasites

(2011) Noah S. Butler et al.   Cell Host & Microbe

Safety and efficacy of the RTS,S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

(2011) Kwaku Poku Asante et al.   LANCET INFECTIOUS DISEASES

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

(2011) Ally Olotu et al.   LANCET INFECTIOUS DISEASES

Protection against Malaria by MSP3 Candidate Vaccine

(2011) Sodiomon B. Sirima et al.   NEW ENGLAND JOURNAL OF MEDICINE

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

A Field Trial to Assess a Blood-Stage Malaria Vaccine

(2011) Mahamadou A. Thera et al.   NEW ENGLAND JOURNAL OF MEDICINE

Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity

(2011) J. E. Epstein et al.   SCIENCE

Development of a metabolically active, non-replicating sporozoite vaccine to preventPlasmodium falciparummalaria

(2010) Stephen L. Hoffman et al.   Human vaccines & immunotherapeutics

Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial

(2010) Pedro Aide et al.   PLoS One

Acquired Immunity to Malaria

(2009) D. L. Doolan et al.   CLINICAL MICROBIOLOGY REVIEWS

Long‐Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican Children

(2009) Jahit Sacarlal et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

(2009) Kent E. Kester et al.   JOURNAL OF INFECTIOUS DISEASES

Protection against a Malaria Challenge by Sporozoite Inoculation

(2009) Meta Roestenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya

(2009) Bernhards R. Ogutu et al.   PLoS One

Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children

(2009) Caterina Guinovart et al.   PLoS One

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area

(2009) Mark E. Polhemus et al.   PLoS One

Contrasting Population Structures of the Genes Encoding Ten Leading Vaccine-Candidate Antigens of the Human Malaria Parasite, Plasmodium falciparum

(2009) Alyssa E. Barry et al.   PLoS One

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali

(2009) Issaka Sagara et al.   VACCINE

Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age

(2008) Philip Bejon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants

(2008) Salim Abdulla et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

(2008) Kent E. Kester et al.   VACCINE